This podcast activity will discuss the practical application of data and frequently asked questions from the independent satellite symposium, Demystifying the Evolving Science and Potential Role of Incretins in T2D, presented at IDF World Diabetes Congress on December 6, 2022.
Speakers
Bernhard Ludvik, MD
Associate Professor of Medicine
Head 1st Medical Department
Landstrasse Clinic
Vienna, Austria
Prof. Bernhard Ludvik, M.D., is Head of the 1st Medical Department with Diabetology, Endocrinology and Nephrology as well of the Karl Landsteiner Institute of Obesity and Metabolic Disorders at the Landstrasse Clinic, Vienna Health Organization, in Vienna, Austria. He is an Associate Professor of Medicine at the Medical University of Vienna. Bernhard Ludvik is a specialist in Internal Medicine and in Endocrinology & Diabetology.
He completed his medical education at the University of Vienna and at the Division of Endocrinology of UCSD in California. Dr. Ludvik served as vice chairman of the Division of Endocrinology at the Medical University of Vienna/General Hospital (AKH) before being appointed Head of the 1st Medical Department of the Landstrasse Clinic.
He obtained numerous awards and was president of the Austrian Diabetes Association and the Austrian Obesity Association. Currently, he is Associate Editor of Obesity Facts and has served on several editorial boards of scientific journals including Diabetologia.
He is author/coauthor of more than 180 papers in peer reviewed journals (h-index 54) and serves as reviewer for various top journals. Dr. Ludvik and his team conduct several studies in the areas of diabetes, metabolism, lipid disorders and kidney diseases in phases 2 and 3 as well as academic studies.
Thomas Forst, MD
Johannes Gutenberg University Mainz
Chief Medical Officer, Chairman of the Executive Board
Clinical Research Services
Mannheim, Germany
Professor Thomas Andreas Forst is a certified physician for internal medicine and endocrinology. In 1989, he started his postdoctoral clinical research work at the German Diabetes Research Institute (Leibnitz Institute) at the Heinrich Heine University in Düsseldorf, Germany. In 1999, he completed his academic training in Internal Medicine and Endocrinology at the 3rd Medical Department for Internal Medicine at the Johannes Gutenberg University in Mainz, Germany. Thereafter, he served as a Clinical Research Physician at Eli Lilly Indianapolis and was responsible for several clinical trials with new drugs for the treatment of diabetes mellitus and its vascular complications. In 2001 he took over the position of the CEO and Medical Director of a clinical research unit with special alignment to diabetes and metabolic research (Institute for Clinical Research and Development, Mainz, Germany). In March 2013, Professor Forst joined the Profil Institute, where he established a new clinical research unit in the city of Mainz. Until the end of 2017 he served as the CEO and Director for Medical Science at the Profil Institute Mainz. In January 2018 Professor Forst joined Clinical Research Services Andernach, Germany, where he is now serving as the Chief Medical Officer and Chairman of the Executive Board.
Since 2001 Professor Forst is a teaching professor for Internal Medicine and Endocrinology at the Johannes Gutenberg University in Mainz. Within the last 30 years, Professor Forst was involved in more than 300 clinical trials mainly in the indication of obesity, metabolic diseases, diabetes mellitus, and cardiovascular complications. He is a member of the American, European and German Diabetes Association. Thomas Forst serves as the chairman of the study group Diabetes and Heart and a board member of the neuropathy study group of the German Diabetes Association. Professor Forst has authored or co-authored in excess of three-hundred original articles in peer reviewed National and International Journals. He is a member of several national and international Editorial Boards and an Associate Editor of Diabetes Endocrinology & Diabetes.
Accreditation and Disclosure Information
TARGET AUDIENCE
This CE activity is intended for endocrinologists, diabetologists, and endocrinology fellows who provide care for individuals with T2D.
EDUCATIONAL OBJECTIVES
After completing this CE activity, participants should be better able to:
-
Assess the potential role of a dual GIP and GLP-1R agonist in treating individuals with T2D and obesity
AGENDA
- Growing global burden of T2D and obesity; Clinical inertia as a contributing factor
- Brief introduction to additive and complementary effects of dual agonism and the first-in class agent
- Tirzepatide's potential role in therapy for T2D; Inclusion in ADA/EASD 2022 consensus report for glucose control as well as weight management
- Practical tips from the EU label, including safety and tolerability; FDA fast track designation for obesity
ACCREDITATION, SUPPORT and CREDIT
In support of improving patient care, Medical Learning Institute, Inc. is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
PHYSICIAN CONTINUING MEDICAL EDUCATION
Medical Learning Institute, Inc. designates this enduring material for a maximum of 0.25 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
SUPPORT STATEMENT
This activity is supported by an educational grant by Lilly.
DISCLOSURE & CONFLICT OF INTEREST POLICY
Medical Learning Institute, Inc. is committed to providing high quality continuing education to healthcare professionals, as individuals and teams, with a protected space to learn, teach, and engage in scientific discourse free from influence from ineligible companies that may have an incentive to insert commercial bias into education. To that end, we require faculty, presenters, planners, staff, and other individuals who are in a position to control the content of this CE activity to disclose all financial relationships they have had in the past 24 months with ineligible companies as defined by the ACCME, as related to the content of this CE activity, regardless of the amount or their view of the relevance to the education. All identified COI will be thoroughly vetted and mitigated according to policy. These disclosures will be provided to learners prior to the start of the CE activity.
FACULTY DISCLOSURES
Planner/Presenter
Bernhard Ludvik, MD
Associate Professor of Medicine
Head, 1st Medical Department
Landstrasse Clinic
Vienna, Austria
Bernhard Ludvik, MD, has a financial interest/relationship or affiliation in the form of:
Research Grant: Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Eli Lilly, Madrigal Pharmaceuticals, Novo Nordisk, Sanofi
Advisory Board/Consultant: Amgen, Boehringer Ingelheim, Daiichi Sankyo, Eli Lilly, Merck Sharp & Dohme, Novartis, Novo Nordisk, Sanofi
Speakers’ Bureau: Amgen, Boehringer Ingelheim, Daiichi Sankyo, Eli Lilly, Merck Sharp & Dohme, Novartis, Novo Nordisk, Sanofi
Planner/Presenter
Thomas Forst, MD
Johannes Gutenberg University Mainz
Chief Medical Officer, Chairman of the Executive Board
Clinical Research Services
Mannheim, Germany
Thomas Forst, MD, has a financial interest/relationship or affiliation in the form of:
Advisory Board/Consultant: AstraZeneca, Atrogi, Bayer, Cipla, Eli Lilly, EyeSense, Fortbildungskolleg, Novo Nordisk, Pfizer, Sanofi, reMYND, Roche
Speakers’ Bureau: Amarin, AstraZeneca, Boehringer Ingelheim, Berlin Chemie, Cipla, Daiichi Sankyo, Eli Lilly, Fortbildungskolleg, Merck Sharp & Dohme, Novartis, Novo Nordisk, Sanofi, Santis
All of the relevant financial relationships of individuals for this activity have been mitigated.
PLANNING COMMITTEE AND CONTENT/PEER REVIEWERS
The planners and content/peer reviewers from Medical Learning Institute, Inc., the accredited provider, do not have any relevant financial relationship(s) to disclose with ineligible companies unless listed below.
DISCLOSURE OF UNLABELED USE
This educational activity may contain discussions of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this CE activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the CE activity are those of the presenters and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
DISCLAIMER
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this CE activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this CE activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
METHOD OF PARTICIPATION
There are no fees for this activity. To claim credit, participants must listen to the episode in its entirety, click the link in the show notes and complete the post-test and evaluation. A passing score of 70% or higher is needed to obtain credit. Once requirements are completed, the certificate will be emailed to you.
For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.
If you have questions regarding your certificate, please contact Mary Vu via email at mvu@mlieducation.org.
ABOUT THIS ACTIVITY
Medical Learning Institute, Inc. is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this CE activity. Our activities may contain references to unapproved products or uses of these products in certain jurisdictions. The preparation of this activity is supported by educational grants subject to written agreements that clearly stipulate and enforce the editorial independence of Medical Learning Institute, Inc.
The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of Medical Learning Institute, Inc. or any of its partners, providers, and/or supporters.
Copyright © 2022 Medical Learning Institute, Inc. All Rights Reserved.